DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the BETA DRUGS LIMITED (BETA) share price today?

BETA DRUGS LIMITED (BETA) is trading at ₹2,229.1 on the NSE, down 1.40% on the day. Source: DocStoX.

What is the PE ratio of BETA DRUGS LIMITED?

BETA DRUGS LIMITED has a price-to-earnings (PE) ratio of 54.5 in the Healthcare sector.

What is the market capitalisation of BETA DRUGS LIMITED?

BETA DRUGS LIMITED has a market capitalisation of approximately ₹0 crore.

BETA DRUGS LIMITED

BETA·NSE·Healthcare

₹2,229.10▼ -31.60 (-1.40%)

Healthcare · Pharmaceuticals

A steady, established business

Day₹2206.80

₹2389.00

52W₹990

₹242486%

Open

₹2280.00

High

₹2389.00

Low

₹2206.80

Prev Close

₹2260.70

Volume

42.5K

VWAP

₹2281.64

Snapshot

Key fundamentals

Market Cap

₹0 Cr

P/E Ratio

54.47Expensive

P/B Ratio

9.07

EPS

₹40.92

Book Value

₹241.00

ROE

18.80%Strong

ROCE

19.00%Efficient

Dividend Yield

0.00%

Debt / Equity

0.60Moderate

Face Value

₹10.00

52W High

₹2424.30

52W Low

₹990.10

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

Narrow moatHigh uncertainty

Fair value estimate

₹350

▼ 84.3%downside

Trading at ₹2,229 — 84% above our estimate

BearFair valueBull

₹298₹350₹471

/100

Business quality — Watch the fundamentals

Growth 58Profitability 59Efficiency 28Valuation 35

Plain English

Our view

A steady, established business
Revenue compounding 19% over 3 years
Fundamental red flags (Piotroski 1/9)

Strengths

Revenue compounding 19% over 3 years
Promoters hold a controlling stake

Risks

Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

19% ROE fading to 13% over ~10 yrs, on ₹241 book

₹317

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹471

Analyst target

No analyst coverage

—

Blended fair value₹350

What the numbers say

Investment thesis

Bull case

Revenue compounding 19% over 3 years
Promoters hold a controlling stake

Bear case

Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

54.5Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

18.8%Strong

Above 15% is considered healthy for Indian equities

ROCE

19.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.60Moderate

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

—

P/B

9.07

EPS

₹40.92

Div Yield

—

What changed

Recent changes

Foreign investors-1.9% stake last quarter
Domestic institutions+0.2% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 54.5×

Growth

Strong

+19% rev CAGR

Profitability

Excellent

18.8% ROE

Financial health

Comfortable

D/E 0.60

Momentum

N/A

No technicals

Today

Trading activity

Delivery %29.6%

Turnover₹969.79L Cr

Trades8,527

VWAP₹2281.64

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+19.3%

+27.1%

10Y

—

Profit

+9.8%

+27.9%

10Y

—

EPS

+10.4%

+28.7%

10Y

—

Profile

Cons

Stock is trading at 9.80 times its book value
Though the company is reporting repeated profits, it is not paying out dividend

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Foreign investors sold 1.93 pts; domestic institutions added 0.22 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

59%

Promoter

Promoters

59.1%0.00

Public

33.6%+10.93

FII / FPI

1.0%-1.93

DII

6.2%+0.22

Quarterly trend

Ownership over time

Q1 FY27

Promoter59.10%

FII1.02%

DII6.23%

Public33.65%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Beta Drugs Ltd is engaged in manufacturing of a wide range of oncology (anti-cancer) drugs in India. It has operations in the domestic and export markets.[1]